An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma

Backgroundβ-glucan has been reported to be a potential natural immune modulator for tumor growth inhibition. We aimed to evaluate the efficacy and safety of β-glucan plus immunotherapy and chemotherapy in the first-line treatment of advanced gastric adenocarcinoma.MethodsThis is a phase IB, prospect...

Повний опис

Бібліографічні деталі

Автори:	Yunqian Chu, Xuan He, Ya Xue, Hua Jiang, Chan Zhu, Chunjian Qi, Xing Zhang, Dongsheng Chen, Hanjue Dai, Qingying Xian, Wenyu Zhu
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2024-08-01
Серія:	Frontiers in Immunology
Предмети:	β-glucan camrelizumab chemotherapy first-line gastric cancer
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1448485/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!